Although this can be overcome by identifying biomarkers to select patients who are most likely to respond to each p53-based therapeutic agent, it requires a deeper understanding of the mechanisms underlying the GOF of mutant p53 in each cancer type. This evidence concerns the gene TP53 and cancer.